Feraheme

Feraheme is a brand name of ferumoxytol, approved by the FDA in the following formulation(s):

FERAHEME (ferumoxytol - solution; intravenous)

• 
  Manufacturer: AMAG PHARMS INC
  
  Approval date: June 30, 2009
  
  Strength(s): EQ 510MG IRON/17ML (EQ 30MG IRON/ML) ^[RLD]

Has a generic version of Feraheme been approved?

No. There is currently no therapeutically equivalent version of Feraheme available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Feraheme. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
  Patent 6,599,498
  Issued: July 29, 2003
  Inventor(s): Ernest V.; Groman & Kenneth G.; Paul & Timothy B.; Frigo & Howard; Bengele & Jerome M.; Lewis
  Assignee(s): Advanced Magnetics, Inc.
  Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.
  
  Patent expiration dates:
  
  
  • March 8, 2020
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
  Patent 7,553,479
  Issued: June 30, 2009
  Inventor(s): Groman; Ernest V. & Paul; Kenneth G. & Frigo; Timothy B. & Bengele; Howard & Lewis; Jerome M.
  Assignee(s): AMAG Pharmaceuticals, Inc.
  Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.
  
  Patent expiration dates:
  
  
  • March 8, 2020
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
  Patent 7,871,597
  Issued: January 18, 2011
  Inventor(s): Groman; Ernest V. & Paul; Kenneth G. & Frigo; Timothy B. & Bengele; Howard & Lewis; Jerome M.
  Assignee(s): AMAG Pharmaceuticals, Inc.
  Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.
  
  Patent expiration dates:
  
  
  • March 8, 2020
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 30, 2012 - NEW PRODUCT
  
  

See also...

• Feraheme Consumer Information (Drugs.com)
• Feraheme Consumer Information (Wolters Kluwer)
• Feraheme Consumer Information (Cerner Multum)
• Feraheme Advanced Consumer Information (Micromedex)
• Feraheme AHFS DI Monographs (ASHP)
• Ferumoxytol Consumer Information (Wolters Kluwer)
• Ferumoxytol Consumer Information (Cerner Multum)
• Ferumoxytol Intravenous Advanced Consumer Information (Micromedex)
• Ferumoxytol AHFS DI Monographs (ASHP)